New data show commercially insured patients face increasingly high cost sharing for brand medicines
By Gabby Migliara | July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
Medicare’s 55th anniversary: Celebrating the success of Part D
By Tom Wilbur | July 30, 2020
Today, we are excited to bring you a special edition of our Medicare Catalyst series in honor of Medicare’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions
By Gabby Migliara | July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | July 22, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
PhRMA submits comments to CMS on Medicaid proposed rule
By Nicole Longo | July 21, 2020
In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts...
Read More
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
By Andrew Powaleny | July 21, 2020
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing...
Read More
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
By Nicole Longo | July 16, 2020
There has been a lot of focus of late on where active pharmaceutical ingredients (APIs) for medicines are manufactured. While some may claim we are reliant on other countries, putting us at risk...
Read More
New report explores setbacks that bring future cancer success stories
By Giovanni Caforio, M.D. | July 16, 2020
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst...
Read More
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
By Gabby Migliara | July 14, 2020
A new study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite...
Read More
Three reasons why MedPAC’s latest Part D proposal would be bad for patients
By Tom Wilbur | July 14, 2020
The recently released Medicare Payment Advisory Commission’s (MedPAC) report to Congress recommends restructuring the Medicare Part D benefit and allowing plans greater flexibility to implement...
Read More
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
By Sarah Sutton | July 13, 2020
Recently, Lori Reilly, Chief Operating Officer at PhRMA, participated in a podcast with the Council of State Governments (CSG) to discuss the important work the biopharmaceutical industry is doing...
Read More
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
By Jocelyn Ulrich | July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
New initiative to bridge the gap on antimicrobial innovation
By Stephen J. Ubl | July 9, 2020
Today, more than 20 leading biopharmaceutical companies are launching the AMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new...
Read More
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
By Tom Wilbur | July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
